ID   PC-3-TxR
AC   CVCL_ZX05
DR   cancercelllines; CVCL_ZX05
DR   Wikidata; Q102114738
RX   PubMed=17440963;
RX   PubMed=29662635;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 6
//
RX   PubMed=17440963; DOI=10.1002/pros.20581;
RA   Takeda M., Mizokami A., Mamiya K., Li Y.-Q., Zhang J., Keller E.T.,
RA   Namiki M.;
RT   "The establishment of two paclitaxel-resistant prostate cancer cell
RT   lines and the mechanisms of paclitaxel resistance with two cell
RT   lines.";
RL   Prostate 67:955-967(2007).
//
RX   PubMed=29662635; DOI=10.18632/oncotarget.24609;
RA   Machioka K., Izumi K., Kadono Y., Iwamoto H., Naito R., Makino T.,
RA   Kadomoto S., Natsagdorj A., Keller E.T., Zhang J., Mizokami A.;
RT   "Establishment and characterization of two cabazitaxel-resistant
RT   prostate cancer cell lines.";
RL   Oncotarget 9:16185-16196(2018).
//